Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease

Table 1

Pre- and postoperative hormonal data of overall acromegalic patients () during longitudinal follow-up; postglucose GH nadir levels are additionally categorized by sex and tumor size. Mean ± SD values are shown.

Parameter	Preoperative	Phase 1	Phase 2	Phase 3
Mean (years)	—	0.7 ± 0.4	6.9 ± 5.4	17.2 ± 8.4
Age (years)	40.4 ± 12.3	45.1 ± 11.3	50.7 ± 11.0	55.4 ± 11.3
IGF-I (SDS)	9.6 ± 5.2	0.6 ± 1.9	−0.32 ± 0.9	−0.28 ± 1.1
Basal GH (μg/L)	19.9 ± 20.4	1.1 ± 0.9	1.0 ± 1.4	0.9 ± 1.2
Range	(1.0–73.0)	(0.0–3.0)	(0.0–7.0)	(0.0–4.4)
Nadir GH (μg/L)	16.0 ± 21.9	0.39 ± 0.38	0.27 ± 0.29	0.22 ± 0.20
Female ()	19.6 ± 27.7	0.45 ± 0.42	0.27 ± 0.25	0.24 ± 0.21
Male ()	11.2 ± 9.5	0.30 ± 0.30	0.29 ± 0.37	0.21 ± 0.19
Micro ()	7.2 ± 6.0	0.27 ± 0.29	0.22 ± 0.27	0.18 ± 0.18
Macro ()	27.0 ± 28.5^a	0.51 ± 0.42	0.31 ± 0.31	0.25 ± 0.21

Phase 1: at the time of remission.
Phase 2: at the time of the last available assessment with the GH assay standardized to IS 80/505.
Phase 3: after a long-term follow-up with ultrasensitive GH assay standardized to IS 98/574.
Micro: microadenoma; macro: macroadenoma.
versus phase 1.
versus microadenoma.